The multivariable-adjusted association between baseline Lp(a) level (log transformed) and ASCVD risk was modeled continuously using generalized additive models, and the association between baseline ...

The 2018 AHA/ACC Multisociety Guideline on the Management of Blood Cholesterol recommends to target an LDL-C <70mg/dL in very high risk ASCVD patients. If the patient is on maximally tolerated statin ...

The risk assessment code, G0537, would cover the administration of an ASCVD risk assessment tool such as ACC’s ASCVD Risk Estimator or the American Heart Association’s PREVENT Tool. The assessment ...

However, the 2016 European prevention guidelines and the 2018 AHA/ACC multisociety cholesterol guidelines have updated this approach and now recognise South Asian ethnicity as a risk enhancer when ...

Compared to estimated LDL-C, eLDL-TG was a better risk marker for primary ... Models for the incident ASCVD event were adjusted for nonlipid variables comparable to those used in the American College ...

The American College of Cardiology/American Heart Association ... that elevated lipoprotein (Lp(a)) remains an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) (1, 2). High ...

While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death among U.S. adults. Despite declining rates of ASCVD mortality, significant disparities across multiple social and ...

Recent discussions, including a KOL webinar featuring Dr. Dipender Gill, emphasized the genetic validation for IL-6 inhibition, a strategy showing promise in reducing ASCVD risk. The company ...